专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08652526B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
标题翻译：用于抑制纤维化的药物载体和药物载体试剂盒
公开(公告)号：US08652526B2
公开(公告)日：2014-02-18
申请号：US13439330
申请日：2012-04-04
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11 , A61K38/18
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

2. 发明申请

US20080193512A1 Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis 有权
标题翻译：用于抑制纤维化的药物载体和药物载体试剂盒
公开(公告)号：US20080193512A1
公开(公告)日：2008-08-14
申请号：US11793736
申请日：2005-12-22
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K31/07 , A61P35/00
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

3. 发明授权

US08591953B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
公开(公告)号：US08591953B2
公开(公告)日：2013-11-26
申请号：US13439330
申请日：2012-04-04
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11 , A61K38/18
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

4. 发明授权

US08178124B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
公开(公告)号：US08178124B2
公开(公告)日：2012-05-15
申请号：US13249072
申请日：2011-09-29
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

5. 发明申请

US20120076852A1 DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS 有权
标题翻译：用于抑制纤维化的药物载体和药物载体工具包
公开(公告)号：US20120076852A1
公开(公告)日：2012-03-29
申请号：US13249072
申请日：2011-09-29
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K47/10 , A61P1/16 , A61P1/18 , C07C35/18 , A61P11/04 , A61K31/7088 , A61K48/00 , A61K9/127 , A61P35/00
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

6. 发明申请

US20130011464A2 DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS 有权
标题翻译：用于抑制纤维化的药物载体和药物载体工具包
公开(公告)号：US20130011464A2
公开(公告)日：2013-01-10
申请号：US13439330
申请日：2012-04-04
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K47/10 , A61K9/14 , A61K38/18 , A61K31/713 , A61P1/16 , A61K38/17 , A61P31/14 , A61P35/00 , A61P1/18 , A61K9/127 , A61K31/7088
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

7. 发明授权

US08173170B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
标题翻译：用于抑制纤维化的药物载体和药物载体试剂盒
公开(公告)号：US08173170B2
公开(公告)日：2012-05-08
申请号：US11793736
申请日：2005-12-22
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

8. 发明授权

US06268336B1 Pharmaceutical composition for treatment of hepatic diseases 失效
标题翻译：用于治疗肝病的药物组合物
公开(公告)号：US06268336B1
公开(公告)日：2001-07-31
申请号：US09202614
申请日：1998-12-18
申请人： Yoshiro Niitsu , Junji Kato , Masato Higuchi
发明人： Yoshiro Niitsu , Junji Kato , Masato Higuchi
IPC分类号： A61K3816
CPC分类号： A61K38/1816
摘要： The present invention relates to a pharmaceutical composition for treatment of hepatic diseases which comprises erythropoietin as an active ingredient to reduce excess iron ions in the liver of a mammal with hepatic diseases, thus improving hepatic functions of said mammal. According to the present pharmaceutical composition with erythropoietin as an active ingredient, excess iron ions in the liver of a mammal with hepatic diseases can be decreased, so it is effective for treatment of chronic hepatitis, hepatic carcinoma, hepatocirrhosis etc. due to excess iron ions. Further, patient's anemia accompanying venesection can be prevented while excretion of excess iron ions can be promoted by using the venesection therapy in combination with the administration of said pharmaceutical composition. Furthermore, the pharmaceutical composition of the present invention is administered into a patient with chronic hepatitis C for whom IFN therapy is not effective to improve hepatic functions after which conventional IFN therapy is conducted whereby its therapeutic effect on said hepatitis can be expected.
摘要翻译：本发明涉及一种用于治疗肝病的药物组合物，其包含红细胞生成素作为活性成分，以减少具有肝脏疾病的哺乳动物肝脏中过量的铁离子，从而改善所述哺乳动物的肝功能。根据本发明的具有红细胞生成素作为活性成分的药物组合物，可以减少具有肝脏疾病的哺乳动物肝脏中的过量铁离子，因此由于过量的铁离子对治疗慢性肝炎，肝癌，肝硬化等有效。此外，通过与所述药物组合物的给药相结合，可以通过使用Venesection治疗来促进排泄过量铁离子，同时可以预防患有血液循环的贫血。此外，将本发明的药物组合物施用于慢性丙型肝炎患者，其中IFN治疗对于改善肝功能无效，之后进行常规IFN治疗，从而可以预期其对所述肝炎的治疗效果。

9. 发明申请

US20050084959A1 Immortalized mesenchymal cells and utilization thereof 审中-公开
标题翻译：永生化间充质细胞及其利用
公开(公告)号：US20050084959A1
公开(公告)日：2005-04-21
申请号：US10493868
申请日：2002-10-31
申请人： Hirofumi Hamada , Yutaka Kawano , Kiminori Nakamura , Masayoshi Kobune , Osamu Honmou , Atsushi Tanooka , Shin-ichi Oka , Katsunori Sasaki , Hajime Tsuda , Yoshinori Ito , Junji Kato , Takuya Matsunaga , Yoshiro Niitsu
发明人： Hirofumi Hamada , Yutaka Kawano , Kiminori Nakamura , Masayoshi Kobune , Osamu Honmou , Atsushi Tanooka , Shin-ichi Oka , Katsunori Sasaki , Hajime Tsuda , Yoshinori Ito , Junji Kato , Takuya Matsunaga , Yoshiro Niitsu
IPC分类号： A61K35/12 , A61K35/18 , A61K35/28 , A61K35/32 , C12N5/0775 , C12N5/078 , C12N5/08
CPC分类号： C12N5/0618 , A61K35/18 , A61K35/28 , A61K35/32 , A61K2035/124 , C12N5/0641 , C12N5/0663 , C12N2503/02 , C12N2506/1353 , C12N2510/04
摘要： The method developed herein is for expanding cord blood-derived hematopoietic stem cells to a degree that is sufficiently safe for clinical application, such as the transplantation of hematopoietic stem cells into adult patients. Further, to prepare a number of mesenchymal stem cells or mesenchymal cells that have conventionally been available only in an extremely small number, an immortalizing gene such as that of telomerase is introduced alone into mesenchymal stem cells, mesenchymal cells or the like, so as to induce the differentiation of the expanded mesenchymal stem cells.
摘要翻译：本文开发的方法是将脐带血衍生的造血干细胞扩增至对临床应用足够安全的程度，例如将造血干细胞移植到成年患者中。此外，为了制备通常仅以极小数目可获得的许多间充质干细胞或间充质细胞，将端粒酶等永生化基因单独导入间充质干细胞，间充质细胞等，以诱导扩大的间充质干细胞的分化。

10. 发明授权

US5843677A Method of assaying asialoglycoprotein receptor and assay reagent therefor 失效
标题翻译：测定脱唾液酸糖蛋白受体的方法及其试剂
公开(公告)号：US5843677A
公开(公告)日：1998-12-01
申请号：US722153
申请日：1996-10-18
申请人： Yoshiro Niitsu , Yutaka Kohgo , Junji Kato , Hirokazu Yago , Hisashi Hanada , Koji Ushizawa
发明人： Yoshiro Niitsu , Yutaka Kohgo , Junji Kato , Hirokazu Yago , Hisashi Hanada , Koji Ushizawa
IPC分类号： G01N33/53 , G01N33/531 , G01N33/543 , G01N33/577 , G01N33/68 , C07K16/28
CPC分类号： G01N33/68
摘要： The present invention is directed to a method of immunoassay of asialoglycoprotein receptors (AGPR) by bringing a specimen into contact with a monoclonal antibody that recognizes AGPR, wherein the pH of a diluted specimen solution is adjusted from 5 to 7 or phenol is added to a solution of an enzyme-labeled antibody. This method is excellent in the sensitivity and accuracy of AGPR assay and can be applied also to the screening of hepatopathy remedies.
摘要翻译： PCT No.PCT / JP95 / 00770 Sec。 371日期：1996年10月18日 102（e）日期1996年10月18日PCT提交1995年4月19日PCT公布。 WO95 / 29403 PCT出版物日期：1995年11月2日本发明涉及一种通过使样品与识别AGPR的单克隆抗体接触的免疫测定来测定脱唾液酸糖蛋白受体（AGPR）的方法，其中将稀释样品溶液的pH调节为5〜7或将苯酚加入到酶标记抗体的溶液中。该方法在AGPR测定的灵敏度和准确性方面优异，也可用于筛查肝病治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式